 WESTLAKE VILLAGE, Calif., July 21, 2021 GLOBE NEWSWIRE -- In order to address a major limitation of todays most widely used method for gauging severity of plaque psoriasis the PASI scale, Arcutis Biotherapeutics, Inc. Nasdaq: ARQT, in conjunction with leading psoriasis experts, has developed a revised scale that offers greater precision for measuring disease extent and therapeutic effects in patients with mild-to-moderate disease. Arcutis, a late-stage biopharmaceutical company that champions meaningful innovation to address immune-mediated dermatological diseases and conditions, shared details of the new approach in the peer-reviewed scientific journal Dermatology and Therapy . 